Skip to main content

Novel Rx

      Taiwanaise study of factors associated with 5 year mortality in patients after their first biological b,ts DMARDS
      A high
      1 year 1 month ago
      Taiwanaise study of factors associated with 5 year mortality in patients after their first biological b,ts DMARDS A highter risque mortality in RTX and lower in tsDMARD vs TNFi @RheumNow @Janetbirdope @Yuz6Yusof https://t.co/rjpo08Tg46
      #ACR23 Great debate: should we use biologics at PMR/GCA onset?

      Dr Spiera (Cons)
      -Need to agree on clin important diff
      1 year 1 month ago
      #ACR23 Great debate: should we use biologics at PMR/GCA onset? Dr Spiera (Cons) -Need to agree on clin important diff & flares -No evidence as disease modifying in GCA - No need for disease modifying in PMR -Most pts can be treated with steroid & rapid taper -Cost @RheumNow https://t.co/ptM8E7EQzF
      #ACR23 Great Debate @ACRheum @RheumNow
      Should you start with upfront bDMARD in #PMR and #GCA?
      1 year 1 month ago
      #ACR23 Great Debate @ACRheum @RheumNow Should you start with upfront bDMARD in #PMR and #GCA?
      Real World SLE Rx patterns from the SPOCS cohort. 70+% IFN high, 81% on antimalarials, 21% biologics, and 55% IS, 65% GC
      1 year 1 month ago
      Real World SLE Rx patterns from the SPOCS cohort. 70+% IFN high, 81% on antimalarials, 21% biologics, and 55% IS, 65% GCs. High IFN pts had more IS and steroid use. 45+% still on GCs at 12 months despite avail of new therapeutics @RheumNow #ACR23 abst#0592
      STOP-JIA study data from Abs #0831 suggest improved effectiveness with early combination tx vs step up and biologic firs
      1 year 1 month ago
      STOP-JIA study data from Abs #0831 suggest improved effectiveness with early combination tx vs step up and biologic first tx at the 2-3 yr timeframe for pJIA pts. More data needed to optimize outcomes/tx for these children. https://t.co/vWL5J4FPbo #ACR23 @rheumnow https://t.co/5iJpwglhPu
      ABS0524:

      ⭐️Benefit of Certolizumab (CZP) over standard non-biologic tx in reducing acute anterior uveitis (AAU) fl
      ABS0524: ⭐️Benefit of Certolizumab (CZP) over standard non-biologic tx in reducing acute anterior uveitis (AAU) flares among high risk pts w/ axSpA ➡️active dz, HLAB27+, 2 or more AAU flares ⭐️CZP reduced AAU flare rate by 87% #ACR23 @RheumNow #ACRBest https://t.co/rW0N18agMO
      SpA Insights: New Therapies
      LTE of REOVAS of RTX in EGPA. Relapse free survival 64% vs 51%, major relapse free 90% vs 79%. If MPO+ relapse free surv
      1 year 1 month ago
      LTE of REOVAS of RTX in EGPA. Relapse free survival 64% vs 51%, major relapse free 90% vs 79%. If MPO+ relapse free survival 92% vs 50%. Abstr#0854 #ACR23 @RheumNow https://t.co/76hlYRxWhY https://t.co/RSsgxxQKVC
      ×